永安药业（002365）一字跌停，公司实际控制人、董事长陈勇被立案调查并实施留置。 ...

机构指出，5月预计风险偏好还有回升空间，A股将继续呈现风偏回暖、主题轮动的特征，以低机构持仓的主题型交易机会为主。 【财经日历】 20:30 美国3月贸易帐 | 因 盘前必读 | // 外盘怎么样 // | | | | --- | --- | --- | --- | | 名称 | 现价 | 涨跌 | 涨跌幅 | | 道琼斯工业指数 | 41218.83 | -98.60 | -0.24% | | 纳斯达克指数 | 17844.24c | -133.49 | -0.74% | | 标普500 | 5650.38 | -36.29 | -0.64% | 当地时间周一，美股三大指数集体收跌，纳指跌0.74%，标普500指数跌0.64%，道指跌0.24%。 美国影视巨头股价"先跌为敬"，奈飞收跌1.94%，派拉蒙跌1.57%，迪士尼跌0.44%。 大型科技股多数下跌，苹果跌超3%，特斯拉跌逾2%，亚马逊、英特尔跌超1%。 热门中概股涨跌不一，纳斯达克中国金龙指数跌0.04%。金山云涨超4%，富途控股、名创优品涨超2%，好未来、微博涨超1%，小鹏汽车、理想汽车、哔哩 哔哩小幅上涨；极氪跌超2%，蔚来、京东跌超1%，腾讯 ...

Group 1 - Heng Rui Pharmaceutical has officially passed the Hong Kong Stock Exchange listing hearing, with the potential to be listed as early as May [1] - The listing represents a significant step in Heng Rui's internationalization strategy, following its IPO in the A-share market [1] - The company aims to leverage the larger growth opportunities in overseas markets as part of its "innovation + internationalization" dual-driven strategy [1] Group 2 - Neuralink's brain-computer interface device Link has received FDA "breakthrough device" designation, aimed at providing communication solutions for patients with severe speech impairments [2] - This designation will expedite the review process, marking a significant advancement for Neuralink in the brain-computer interface field [2] - However, this certification does not equate to market approval, and further clinical validation and safety assessments are required [2] Group 3 - Novo Nordisk's oral version of the weight loss drug Wegovy has had its application accepted by the FDA, with a decision expected in Q4 [3] - If approved, it will be the first oral GLP-1 receptor agonist for chronic weight management globally, potentially enhancing Novo Nordisk's competitive position in the weight loss market [3] - The oral formulation addresses issues of injection adherence among patients, indicating a broad market opportunity if approved [3] Group 4 - Xianju Pharmaceutical has received an administrative penalty of 195 million yuan for engaging in price-fixing agreements that restricted competition in the market for dexamethasone phosphate raw materials [4] - This significant fine reflects the increasing regulatory scrutiny and enforcement against anti-competitive practices in the pharmaceutical sector [4] - The penalty is expected to have a substantial negative impact on Xianju's short-term performance and highlights weaknesses in the company's compliance framework [4] Group 5 - Yong'an Pharmaceutical's chairman Chen Yong is under investigation and has been detained, although the company states that its operations and management remain stable [5] - The investigation may affect the market's perception of the company's credibility and management stability [5] - Despite assurances of normal operations, there may be short-term pressure on the company's stock price due to the uncertainty surrounding the investigation [5]

Group 1: Corporate Investigations and Issues - China Copper Industry Co., Ltd. director Li Lianbing is under investigation for serious violations of discipline and law [3] - Yong'an Pharmaceutical's actual controller and chairman Chen Yong is under investigation and has been detained [6] - Xianju Pharmaceutical received an administrative penalty of 195 million yuan for price-fixing agreements with competitors [10] Group 2: Corporate Transactions and Financial Warnings - AVIC Capital plans to transfer shares of AVIC Xi'an Aircraft Industry Group and AVIC Avionics to its controlling shareholder for 4.067 billion yuan [7] - Jiangsu Wuzhong's stock will be subject to additional risk warnings due to an audit report with no opinion and non-operational fund occupation by related parties [8] - Tianmao Group and Jinlitai are both unable to disclose their periodic reports on time, leading to stock suspensions [10][11] Group 3: Industry Trends and Changes - Several automotive companies, including Li Auto, Xiaomi, NIO, and Xpeng, are shifting their marketing language from "smart driving" to "assisted driving" [21]

每经编辑 陈鹏程 王晓波 1 隔夜市场 美股三大指数集体收跌，纳指跌0.74%，标普500指数跌0.64%，道指跌0.24%，道指与标普500指数此前连续9个交易日的上涨至此终结；大型科技股多数下 跌，苹果跌超3%，特斯拉跌逾2%，亚马逊、奈飞、英特尔跌超1%，英伟达小幅下跌；微软、谷歌、Meta小幅上涨；伯克希尔-A跌超5%，巴菲特将于2025 年底卸任首席执行官一职。中概股涨跌不一，纳斯达克中国金龙指数跌0.04%；金山云涨超4%，富途控股、名创优品涨超2%，好未来、微博涨超1%，小鹏 汽车、理想汽车、哔哩哔哩小幅上涨；极氪跌超2%，瑞幸咖啡、蔚来、京东、霸王茶姬跌超1%。 国际油价走弱，美油主力合约收跌1.82%，报57.23美元/桶；布伦特原油主力合约跌1.55%，报60.34美元/桶。 国际金价大幅走高，现货黄金涨2.85%，报3332.85美元/盎司；COMEX黄金期货涨3.09%，报3343.50美元/盎司；COMEX白银期货涨1.29%，报32.68美元/盎 司。 欧洲主要股指收盘涨跌不一，德国DAX指数涨1.12%报23344.54点，法国CAC40指数跌0.55%报7727.93点，英国股 ...

Mergers and Acquisitions - Xingye Yinxin plans to acquire Atlantic Tin Company for approximately 4.54 billion RMB, with a total investment of about 0.98 million AUD at a price of 0.24 AUD per share [1] - Electric Power Investment Energy is undergoing an asset restructuring with its actual controller, State Power Investment Corporation, involving the acquisition of Inner Mongolia Baiyin Hua Coal Power equity [2] - Huibo Yuntong intends to purchase control of Baode Computer System Co., Ltd. through a combination of share issuance and cash payment, with details to be disclosed in a restructuring report [3] Share Buybacks and Increases - Kesi Technology plans to repurchase shares worth between 30 million and 50 million RMB, using self-owned funds for employee stock ownership plans or capital reduction [4] - Fuchuang Precision's major shareholder, Shenyang Advanced Manufacturing Technology Industry Co., Ltd., aims to increase its stake in the company by 1.2 billion to 2.4 billion RMB over the next 12 months [5] Regulatory and Compliance Issues - Yong'an Pharmaceutical's actual controller and chairman, Chen Yong, is under investigation and has been detained, with the company monitoring the situation closely [6] - *ST Gongzhi received a notice of termination of listing due to financial reporting issues, including an audit report with no opinion expressed for the 2024 fiscal year [8] - Xianju Pharmaceutical was fined 195 million RMB for engaging in monopolistic practices related to the pricing of dexamethasone phosphate sodium raw materials [9] - *ST Hengli failed to disclose periodic reports within the legal timeframe, leading to potential termination of its stock listing [10] - Tianmao Group also failed to disclose its periodic reports on time, resulting in stock suspension [11]

关于公司实际控制人、董事长被留置的公告 证券代码：002365 证券简称：永安药业 公告编号：2025-31 潜江永安药业股份有限公司 目前，公司尚未知悉上述事项的进展和结论，公司将持续关注上述事项的 进展情况，并严格按照相关规定及时履行信息披露义务。 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》 和巨潮资讯网，公司发布的信息均以在上述媒体刊登的公告为准。敬请广大投 资者注意投资风险。 特此公告。 潜江永安药业股份有限公司 董 事 会 二〇二五年五月五日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）收到公司实际控制人、董 事长陈勇先生家属的通知，其于近日收到由鹤峰县监察委员会签发的关于陈勇 先生的《立案通知书》和《留置通知书》，公司实际控制人、董事长陈勇先生被 立案调查并实施留置。 目前，公司已对相关工作进行了妥善安排。公司拥有完善的治理结构及内 部控制机制，将按照《公司法》、《深圳证券交易所股票上市规则》、《上市公 司治理准则》及《公司章程》等法律法规和相关制度规范运作。 截至本公告披露日 ...

智通财经5月5日电，永安药业(002365.SZ)公告称，公司收到实际控制人、董事长陈勇家属通知，陈勇 被鹤峰县监察委员会立案调查并实施留置。目前公司其他董事、监事和高级管理人员均正常履职，公司 控制权未发生变化，生产经营情况正常。公司将持续关注该事项进展并及时履行信息披露义务。 永安药业：公司实际控制人、董事长陈勇被立案调查并实施留置 ...

Mergers and Acquisitions - Zhongguangtianze plans to acquire 100% equity of Changsha Sports Industry Company for 29.6 million yuan, constituting a related party transaction [1] Earnings Disclosure - JinkoSolar reported a revenue of 13.843 billion yuan for Q1 2025, a year-on-year decrease of 40.03%, with a net loss of 1.39 billion yuan compared to a net profit of 1.176 billion yuan in the same period last year [2] - Zhongjin Gold reported a revenue of 14.859 billion yuan for Q1 2025, a year-on-year increase of 12.88%, with a net profit of 1.038 billion yuan, up 32.65% year-on-year [3] - Northern Rare Earth achieved a revenue of 9.287 billion yuan for Q1 2025, a year-on-year increase of 61.19%, with a net profit of 431 million yuan, up 727.3% year-on-year [4] - Kweichow Moutai reported a revenue of 50.601 billion yuan for Q1 2025, a year-on-year increase of 10.54%, with a net profit of 26.847 billion yuan, up 11.56% year-on-year [5] Share Buybacks - Shanjin International plans to repurchase shares with a total amount between 100 million and 200 million yuan at a price not exceeding 29.7 yuan per share [6] - Sichuan Road and Bridge plans to repurchase shares with a total amount between 100 million and 200 million yuan at a price not exceeding 12.54 yuan per share [7] - China Railway plans to repurchase shares with a total amount between 800 million and 1.6 billion yuan at a price not exceeding 8.5 yuan per share [8] - Anhui Construction's controlling shareholder plans to increase its stake in the company with a total amount not exceeding 200 million yuan [9][10] Risk Matters - Chuangxing Resources' stock will be subject to delisting risk warning starting May 6, 2025, due to negative net profit for the fiscal year 2024 [11] - Yong'an Pharmaceutical clarified that rumors regarding a significant price increase of taurine are untrue [12] - *ST Xulan's stock will be delisted on April 30, 2025, as decided by the Shenzhen Stock Exchange [13] - Dawi Technology's shareholder plans to reduce its stake by up to 3% of the company's total shares due to personal financial needs [14]

近日，潜江永安药业股份有限公司（以下简称"公司"）收到国家知识产权 局颁发的一项发明专利证书，具体内容如下: 证券代码：002365 证券简称：永安药业 公告编号：2025-30 潜江永安药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 专利申请日：2022 年 06 月 22 日 授权公告日：2025 年 04 月 29 日 授权公告号：CN 115141126 B 专利有效期：从申请日开始 20 年 公司为全球牛磺酸领域的知名企业，一直致力于牛磺酸生产技术的研发，该 专利的取得有利于保护和发挥公司主导产品自主知识产权优势，使公司继续在 牛磺酸领域保持技术领先优势,有利于提升公司的核心竞争力，进一步提高公司 牛磺酸产品在国际市场的知名度。该专利的取得暂不会对公司生产经营和业绩 产生重大影响。 特此公告。 发明名称：一种高效循环制备柱状牛磺酸的方法 发明人：陈勇；方锡权；李少波 专利号：ZL 2022 1 0720762.3 专利权人：潜江永安药业股份有限公司 地址：433100 湖北省潜江市潜江经济开发区广泽大道 ...